Search
pexelizumab
Indications:
- of NO benefit in PCI* in association with STEMI* [1]
* percutaneous transluminal coronary intervention (PCI) ST-segment-elevation myocardial infarction (STEMI)
Dosage: 2-mg/kg bolus, the 0.05-mg/kg/hour infusion for 24 hours
Mechanism of action:
1) binds complement C5
- near-complete inhibition of complement activity for 24 hours (with therapeutic dose)
2) anti-inflammatory actions
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- APEX AMI Investigators; Armstrong PW, Granger CB,
Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG,
Vahanian A, Van de Werf F.
Pexelizumab for acute ST-elevation myocardial infarction in
patients undergoing primary percutaneous coronary intervention:
a randomized controlled trial.
JAMA. 2007 Jan 3;297(1):43-51.
PMID: 17200474
- Eikelboom JW, O'Donnell M.
Pexelizumab does not 'complement' percutaneous coronary
intervention in patients with ST-elevation myocardial
infarction.
JAMA. 2007 Jan 3;297(1):91-2. No abstract available.
PMID: 17200480